Related Experiment Video
Updated: Feb 4, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
Clinical correlates of quantitative EEG in Parkinson disease: A systematic review
Victor J Geraedts1, Lennard I Boon1, Johan Marinus1
1From the Department of Neurology (V.J.G., J.M., J.J.v.H., M.R.T., M.F.C.), Leiden University Medical Center; Department of Clinical Neurophysiology and MEG Center (V.J.G., L.I.B., A.A.G., C.J.S.) and Alzheimer Center, Department of Neurology (A.A.G.), VU University Medical Center, Amsterdam; and Department of Neurology (M.F.C.), Haga Teaching Hospital, The Hague, the Netherlands.
Objective:
To assess the relevance of quantitative EEG (qEEG) measures as outcomes of disease severity and progression in Parkinson disease (PD).
Methods:
Main databases were systematically searched (January 2018) for studies of sufficient methodologic quality that examined correlations between clinical symptoms of idiopathic PD and cortical (surface) qEEG metrics.
Results:
Thirty-six out of 605 identified studied were included. Results were classified into 4 domains: cognition (23 studies), motor function (13 studies), responsiveness to interventions (7 studies), and other (10 studies). In cross-sectional studies, EEG slowing correlated with global cognitive impairment and with diffuse deterioration in other domains. In longitudinal studies, decreased dominant frequency and increased θ power, reflecting EEG slowing, were biomarkers of cognitive deterioration at an individual level. Results on motor dysfunction and treatment yielded contrasting findings. Studies on functional connectivity at an individual level and longitudinal studies on other domains or on connectivity measures were lacking.
Conclusion:
qEEG measures reflecting EEG slowing, particularly decreased dominant frequency and increased θ power, correlate with cognitive impairment and predict future cognitive deterioration. qEEG could provide reliable and widely available biomarkers for nonmotor disease severity and progression in PD, potentially promoting early diagnosis of nonmotor symptoms and an objective monitoring of progression. More studies are needed to clarify the role of functional connectivity and network analyses.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Correlations
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Chronic Kidney Disease II: Clinical Manifestations

